Meeting Highlights Information Registration Visa Letter Application Programme Overview Exhibition Virtual Exhibition Hotels Exhibition Virtual Exhibition Satellite Programme


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Corneal graft rejection about one case

Poster Details


First Author: L.Kora MOROCCO

Co Author(s): B. Allali   I. Morsli   T. Elongo   S. Belhantier   L. El Maaloum   A. El Kettani     

Abstract Details

Purpose:

Corneal graft rejection is the major cause of penetrating keratoplasty failure. It is a complex immunological process that will lead to an efferent immune response against the graft. Our purpose is to report a case where early support of this condition lead to a speed recovery of a very good visual acuity.

Setting:

Pediatric ophthalmologic department of hospital 20 aout 1953 of Casablanca in Morocco

Methods:

A diagnostic study, treatment and complete follow up was made in a 44 four years old woman who attended the ophthalmological emergency for a corneal graft rejection management

Results:

Woman of 44 year with history of penetrating keratoplasty 6 years ago for a corneal scar due to contact lens’ abces. She was received to the ophthalmological department complaining of a deep visual acuity loss since 24 hours , with visual fog, and photophobia and watering. After an immediate hospitalization, EKG and kaliemia were normal. The patient received and intensive corticotherapy (intra venous, sub conjunctival, and topic by drop). The visual acuity improve from hand motion to 20/25.

Conclusions:

Each layer of the cornea can undergo rejection, endothelial rejection being the most severe form. In some cases, rejection will lead to corneal graft failure. Many risk factors contribute to corneal graft rejection. Corticosteroid therapy, topical or systemic, is used in the preventive and curative treatment of rejection. Other immunosuppressive agents are promising but require further evaluation. Early detection of rejection is the key to establish an aggressive treatment and reduce the risk of graft failure.

Financial Disclosure:

None

Back to Poster listing